In an era where digital communication has become imperative for businesses, Werfen, a global leader in in-vitro diagnostics (IVD) and healthcare solutions, has announced its latest venture - a dedicated WhatsApp channel for the EEMEA (Eastern Europe, Middle East, and Africa) region.
EEMEA is proud to have won the NOVA View® tender in Hungary in November along with the effort of our Werfen Hungary Affiliate, against tough competition.
Werfen Poland and the rest of the team in EEMEA with the support of the SBU installed the first HemoCell in Poland and the second in EEMEA in May 2022.
Werfen and AFMS organized the first Partnership meeting held from March 22nd to March 24th in Dubai, UAE.
The cooperation between Werfen and its local KSA partner, AFMS, is unique.
Werfen implemented Strategic Selling in its commercial methodologies since 2019, as a complementary skillset in addition to the ValueSelling Framework, initiated in 2018.
Back in 2016, Werfen established the first office in the Middle East, in the United Arab Emirates, Dubai, in response to the growing demand for Werfen products in the region.
Diagnostic testing, through accurate results, enables the health care providers in effective delivery of care in today's complex healthcare system, particularly in acute care settings.
In September, King Faisal Specialty Hospital and Research Center (the hospital) confirmed that all inhouse Thrombotic Thrombocytopenic Purpura (TTP) diagnosing and monitoring will be done with HemosIL AcuStar ADAMTS13 Activity assay in a 2-year deal, that includes a Bio-Flash analyzer for its autoimmunity laboratory.
One of the key aspects of clinical value selling is augmentation of ecosystem and market advocacy in the focus areas. Enablement and empowerment of the end user, in terms of clinical application of Werfen products and solutions, continues to drive clinical marketing strategy.

